Affera’s revolutionary lesion formation and mapping platform offers a solution designed to optimize procedural efficiency and efficacy across a broad range of arrhythmias. The expandable lattice tip of the company’s Sphere9™ catheter and integrated system enable the rapid creation of detailed maps as well as controlled, durable lesions in a variety of substrates.

“It has been exciting to participate in the development of Affera’s technology and to translate this work from pre-clinical studies to patient care,” stated Elad Anter, M.D., Director of Electrophysiology Laboratories at Beth Israel Deaconess and Associate Professor of Medicine at Harvard Medical School. “In the initial clinical experience treating Atrial Fibrillation, the system shows extraordinary promise in achieving pulmonary vein isolation with less than three minutes of radiofrequency time. The ability to design and create lines of block such as the cavo-tricuspid and mitral isthmus lines, typically with only seconds of energy delivery, is game-changing.  Furthermore, I am enthusiastic about the impact Affera will have on Ventricular Tachycardia treatment, which currently represents a truly unmet clinical need.”

“Affera is pleased to return to HRS this year to share initial clinical results from our work with leading investigators in Europe, and highlight additional capabilities of our system,” stated Doron Harlev, CEO and founder of Affera. “We are excited by the clinical community’s reception of our technology and look forward to further validation as we work to expand our clinical efforts to the US.”

Source: Company Press Release.